ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
ABNX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012616852 (+1 more)
- LEI:
- 969500785J7VIC5YPC96
- Country:
- France
- Address:
- 33 AVENUE GEORGES POMPIDOU, 31130 BALMA
- Website:
- https://abionyx.com/en/
- Sector:
- Manufacturing
Description
ABIONYX Pharma is a new-generation biotechnology company that develops innovative therapies for indications with no effective or existing treatments. The company leverages extensive expertise in lipid metabolism and is a leader in recombinant apolipoprotein A-I (apoA-I), the primary protein of High-Density Lipoprotein (HDL). Its core technology platform utilizes apoA-I to create novel biotherapies and HDL vectors for targeted drug delivery. Key therapeutic areas of focus include critical illnesses such as sepsis, as well as renal and ophthalmological diseases. The company's strategy involves an integrated approach, combining biotherapy with diagnostics to address complex medical conditions with high unmet needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-13 19:48 |
Inside Information / Other news releases
|
English | 277.5 KB | ||
| 2024-06-04 18:45 |
Total number of voting rights and capital / Information on the total number of …
|
English | 179.6 KB | ||
| 2024-06-04 18:45 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 190.1 KB | ||
| 2024-05-27 18:00 |
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de r…
|
French | 139.4 KB | ||
| 2024-05-27 18:00 |
Total number of voting rights and capital / Information on the total number of …
|
English | 179.6 KB | ||
| 2024-05-27 18:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 190.0 KB | ||
| 2024-05-16 18:00 |
Quarterly financial reporting / First quarter financial report
|
English | 246.8 KB | ||
| 2024-05-16 18:00 |
Information financière trimestrielle / Information financière du premier trimes…
|
French | 244.6 KB | ||
| 2024-05-07 18:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 190.0 KB | ||
| 2024-05-07 18:00 |
Total number of voting rights and capital / Information on the total number of …
|
English | 179.6 KB | ||
| 2024-05-02 18:15 |
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 200.3 KB | ||
| 2024-05-02 18:15 |
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 194.0 KB | ||
| 2024-04-30 19:56 |
DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
|
French | 11.0 MB | ||
| 2024-04-30 19:56 |
DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
|
French | 11.0 MB | ||
| 2024-04-10 18:00 |
Total number of voting rights and capital / Information on the total number of …
|
English | 171.9 KB |
Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIONYX Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-02-28 | N/A | Other | Buy | 53,913 | N/A |
Peer Companies
